AstraZeneca’s late-stage trial failure sends its shares down 16% and Bristol-Myers, Merck stocks seesawing
July 27, 2017 at 08:43 AM EDT
The three pharmaceutical companies are competing to be leaders in treating lung cancer.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|